Finance

Piper Sandler maintains Overweight rating on Skye Bioscience shares By Investing.com

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png https://www.investing.com/news/company-news/piper-sandler-maintains-overweight-rating-on-skye-bioscience-shares-93CH-3607133 Investing.com

Porsche-backed Cylib breaks ground on huge EV battery recycling plant

]> https://image.cnbcfm.com/api/v1/image/108030866-1725878792641-55f1750e-ac79-481b-9bc7-13d2829c06c4.jpg?v=1725878894&w=1920&h=1080 https://www.cnbc.com/2024/09/09/porsche-backed-cylib-breaks-ground-on-huge-ev-battery-recycling-plant.html

RBC Capital stays cautious on Regeneron shares, highlights Factor XI program’s market potential By Investing.com

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png https://www.investing.com/news/company-news/rbc-capital-stays-cautious-on-regeneron-shares-highlights-factor-xi-programs-market-potential-93CH-3607082 Investing.com

Bill Gates says retirement ‘sounds awful’ and wants to be like Warren Buffett

Foundation will celebrate its 25th anniversary next year. We haven’t gotten rid of polio, we haven’t got rid of malaria. I’m very,...

BA, DELL, MRK and more

Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png https://www.investing.com/news/press-releases/medicenna-presents-preclinical-results-from-its-il2-superantagonist-and-antipd1il2-biskit-programs-at-the-promise-of-interleukin2-therapy-conference-93CH-3606969 Investing.com

Latest articles

spot_imgspot_img